Cambridge Cognition highlights positive CANTAB® results in research by Bristol Myers Squib

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group, congratulates Bristol Myers Squibb, the global biopharmaceutical company, for its recent FDA approval of Cobenfy (KarXT™ or Xanomeline and Trospium), and the exciting results published recently in The American Journal of Psychiatry¹ showcasing the use of Cambridge Cognition’s CANTAB product in two Phase 3 clinical trials in patients with schizophrenia.

Marking a significant advancement in schizophrenia treatment, Cobenfy is the first new drug in decades and targets the M1 and M4 muscarinic receptors, compared to antipsychotics which block dopamine receptors. This approach reduces both the positive and negative symptoms of schizophrenia more effectively².

CANTAB digital assessments provide accurate and objective measures of cognitive function in clinical trials, enabling a more targeted approach. The Company notes that Bristol Myers Squibb used data from CANTAB cognitive assessments to conduct a post-hoc analysis of two-Phase 3 trials. This analysis was recently published in The American Journal of Psychiatry¹ titled ‘The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials’.  The CANTAB assessments showed improvement in patients with pre-specified cognitive impairments after treatment with Cobenfy.

Cambridge Cognition believes this highlights CANTAB’s effectiveness in measuring cognitive performance improvements throughout the development of new schizophrenia treatments. We remain committed to assisting pharmaceutical companies in adopting CANTAB, enabling them to leverage cutting-edge study designs and digital data capture technologies for more impactful research.

Rob Baker, Chief Operating Officer and Joint Managing Director at Cambridge Cognition, commented:

“This is an important milestone in schizophrenia treatment’s history, and we are pleased to have been able to play a part. Importantly, this analysis evidences how our digital assessment technologies can streamline data collection, improve trial accuracy and ultimately accelerate the development of effective treatments in schizophrenia.”

References:

1. Horan, William P., et al. "The Impact of Xanomeline and Trospium Chloride on Cognitive Impairment in Acute Schizophrenia: Replication in Pooled Data From Two Phase 3 Trials." American Journal of Psychiatry (2024).
2. Kaul, Inder, et al. "Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline–trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial." The Lancet 403.10422 (2024): 160-170.